Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Chad Mirkin
Northwestern University, Department: Chemistry
Should you be removed from our database? Contact us at [email protected]. Read more below.
AuraSense, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
This research uses nanoparticles as potential therapeutic agents in the treatment of glioblastoma in patients that develop resistance to chemotherapy. The goal is to suppress the expression of the MGMT gene that encodes a DNA methytransferase associated with chemotherapeutic resistance. This will be done using nanoparticles of spherical nucleic acids targeting MGMT. Similar therapeutic approaches using engineered nanoparticles and spherical nucleic acids are a goal of the biotechnology company AuraSense, in which Professor Mirkin is a founder and discloses equity interest. Given the close relationship of the work and goals of AuraSense and this proposal, continued development of these spherical nucleic acids for therapeutic application funded through this grant may result in a perceived conflict of interest that should be managed.
Overcoming Temozolomide Resistance using MGMT-targeting Spherical Nucleic Acids
Glioblastoma multiforme (GBM) is an aggressive type of brain tumor that, despite treatment, typically kills patients within 15 months of initial diagnosis. Our goal is to drastically improve GBM treatment by developing nanoparticles that have the potential to eliminate resistance to chemotherapy. This will improve our ability to destroy tumor cells and increase survival times in patients.
Filed on April 19, 2013.
Tell us what you know about Chad Mirkin's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Chad Mirkin”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Chad Mirkin | Northwestern University at Chicago | Conflict of Interest | Exicure | $100,000 - $149,999 |
| Chad Mirkin | Northwestern University at Chicago | Conflict of Interest | AuraSense Therapeutics, LLC | $5,000 - $9,999 |
| Chad Mirkin | Northwestern University at Chicago | Conflict of Interest | Exicure | $100,000 - $149,999 |
| Chad Mirkin | Northwestern University at Chicago | Conflict of Interest | Exicure | Value cannot be readily determined |
| Chad Mirkin | Northwestern University at Chicago | Conflict of Interest | Exicure | $100,000 - $149,999 |
| Chad Mirkin | Northwestern University at Chicago | Conflict of Interest | Exicure, Inc. | Value cannot be readily determined |
| Chad Mirkin | Northwestern University at Chicago | Conflict of Interest | AuraSense, LLC | Value cannot be readily determined |
| Chad Mirkin | Northwestern University | Conflict of Interest | AuraSense Therapeutics, LLC | $5,000 - $9,999 |
| Chad Mirkin | Northwestern University | Conflict of Interest | AuraSense Therapeutics, LLC | Value cannot be readily determined |
| Chad Mirkin | Northwestern University at Chicago | Conflict of Interest | AuraSense | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.